Lucerum Blog
Home > Blog
Looking for something specific?
Meditation, Measured: How Brain Connectivity Is Reframing an Ancient Practice
Meditation research is increasingly focused on how large-scale brain networks support trainable attention, awareness, and emotion regulation, with the default-mode, frontoparietal-control, and salience networks emerging as central systems of interest. Resting-state mapping with fMRI and source-localized qEEG can track how these networks change with practice, opening a practical path to test whether individual network changes relate to meaningful cognitive and clinical outcomes.
Sleep, Vigilance, and Seizures
Sleep is a pharmacologically active brain state. The sleep-wake cycle continuously regulates cortical excitability, with NREM transitions elevating and REM suppressing seizure susceptibility. A 2025 meta-analysis now provides robust population-level evidence that sleep deprivation measurably reduces cortical inhibition. Many drugs in routine use — across addiction medicine, psychiatry, and pain management — alter the sleep architecture that maintains this inhibitory tone. For alcohol and GABAergic sedatives, the link from sleep disruption to withdrawal seizure is mechanistically direct. For antidepressants, stimulants, and opioids, the sleep-architecture pathway adds a layer of risk that warrants consideration alongside the drugs’ direct pharmacological effects.
Measuring the Rewiring: Connectivity Biomarkers for the Next Generation of Psychiatric Drugs
For pharma teams developing neuroplastogens, from psychedelics to next-generation antidepressants, this piece lays out brain functional connectivity, obtained from EEG or fMRI, as the key biomarker for showing that a drug is reorganizing brain circuits. It covers how Lucerum's standardized qEEG methods turn connectivity into a practical, dose-tracked measure usable across every clinical trial phase, with examples from a real MDD program showing the approach in action, from healthy volunteers through patient outcomes.
Quantitative EEG in Depression: Predictors of Treatment Response
Quantitative EEG in Depression: Predictors of Treatment Response
Antidepressants and rTMS help roughly half of the patients who try them. Nobody knows which half in advance. That's a solvable problem — and quantitative EEG has quietly spent forty years solving it.
In this piece I give a broad overview of where the field actually is: the early generation of qEEG response predictors that have survived four decades of scrutiny and meta-analysis, the shift now underway toward network- and connectome-based markers that match the modern view of depression as a circuit-level disorder, and the emerging frontier of source-localized, neurotransmitter-informed EEG that could turn precision psychopharmacology from an aspiration into a workflow. I close on where things stand with the FDA and payers, and why the momentum is finally moving in the right direction.
qEEG is not a miracle. But the comparison is not qEEG-versus-perfection — it's versus-the-coin-flip. #qEEG, #Neuroscience, #BrainMapping, #Depression, #Psychiatry, #rTMS, #Antidepressants, #Psychopharmacology, #Connectomics
When the Brain Speaks Without Words: Decoding Tacit Knowledge and Intelligence Through Neural Connectivity
In neuroscience and cognitive science, we are often taught that what matters is what can be measured. But some forms of human expertise—like intuition, skill, or insight—have long eluded direct observation. We call this tacit knowledge: knowing how to act, without necessarily being able to say why.
